Englander Institute for Precision Medicine

A Novel Metabolic Signature To Predict the Requirement of Dialysis or Renal Transplantation in Patients with Chronic Kidney Disease.

TitleA Novel Metabolic Signature To Predict the Requirement of Dialysis or Renal Transplantation in Patients with Chronic Kidney Disease.
Publication TypeJournal Article
Year of Publication2019
AuthorsZacharias HU, Altenbuchinger M, Schultheiss UT, Samol C, Kotsis F, Poguntke I, Sekula P, Krumsiek J, Köttgen A, Spang R, Oefner PJ, Gronwald W
JournalJ Proteome Res
Volume18
Issue4
Pagination1796-1805
Date Published2019 Apr 05
ISSN1535-3907
KeywordsAged, Female, Humans, Kidney Transplantation, Male, Metabolome, Metabolomics, Middle Aged, Models, Statistical, Predictive Value of Tests, Renal Dialysis, Renal Insufficiency, Chronic, Risk Assessment
Abstract

Identification of chronic kidney disease patients at risk of progressing to end-stage renal disease (ESRD) is essential for treatment decision-making and clinical trial design. Here, we explored whether proton nuclear magnetic resonance (NMR) spectroscopy of blood plasma improves the currently best performing kidney failure risk equation, the so-called Tangri score. Our study cohort comprised 4640 participants from the German Chronic Kidney Disease (GCKD) study, of whom 185 (3.99%) progressed over a mean observation time of 3.70 ± 0.88 years to ESRD requiring either dialysis or transplantation. The original four-variable Tangri risk equation yielded a C statistic of 0.863 (95% CI, 0.831-0.900). Upon inclusion of NMR features by state-of-the-art machine learning methods, the C statistic improved to 0.875 (95% CI, 0.850-0.911), thereby outperforming the Tangri score in 94 out of 100 subsampling rounds. Of the 24 NMR features included in the model, creatinine, high-density lipoprotein, valine, acetyl groups of glycoproteins, and Ca-EDTA carried the highest weights. In conclusion, proton NMR-based plasma fingerprinting improved markedly the detection of patients at risk of developing ESRD, thus enabling enhanced patient treatment.

DOI10.1021/acs.jproteome.8b00983
Alternate JournalJ Proteome Res
PubMed ID30817158

Weill Cornell Medicine Englander Institute for Precision Medicine 413 E 69th Street
Belfer Research Building
New York, NY 10021